Missouri is currently home to 1899 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Saint Louis, Kansas City, St. Louis and Springfield. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
NCT03516708
Recruiting
The purpose of this research study is to evaluate epacadostat when given with routine radiation therapy and chemotherapy (capecitabine and oxaliplatin) to treat rectal cancer before routine surgery is performed to remove the tumor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Rectal Cancer
Register for Updates
Diaphragmatic Hernia Research & Exploration, Advancing Molecular Science
NCT00950118
Recruiting
The goal of this study is to identify genes that convey susceptibility to congenital diaphragmatic hernia in humans. The identification of such genes, and examination of their structure and function, will enable a delineation of molecular pathogenesis and, ultimately, prevention or treatment of congenital diaphragmatic hernia. There are many different possible modes of inheritance for congenital anomalies, including autosomal dominant, autosomal recessive, and multifactorial. Multi-factorial inh... Read More
Gender:
ALL
Ages:
All
Trial Updated:
04/30/2025
Locations: Washington University Medical Center/ St. Louis Children's Hospital, Saint Louis, Missouri
Conditions: Congenital Diaphragmatic Hernia
Register for Updates
Nasal Obstruction With Oxymetazoline and Corticosteroids
NCT06830109
Recruiting
This study aims to examine the efficacy and safety of commination oxymetazoline/intranasal steroids for long-term management of chronic nasal obstruction that is recalcitrant to the current standard of care. The investigators hypothesize that combination treatment with oxymetazoline and intranasal corticosteroid spray will provide a larger reduction in nasal obstruction than intranasal corticosteroid alone for patients suffering from chronic nasal obstruction, and there will not be occurrences o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/29/2025
Locations: Washington University, Saint Louis, Missouri
Conditions: Nasal Obstruction
Register for Updates
Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer's Disease (AD)
NCT06673069
Recruiting
The primary purpose of this study is to evaluate the safety and tolerability of ION269 in adults with Down syndrome with evidence of brain amyloid positivity.
Gender:
ALL
Ages:
Between 35 years and 55 years
Trial Updated:
04/29/2025
Locations: Ionis Investigative Site, Saint Louis, Missouri
Conditions: Alzheimer Disease, Down Syndrome
Register for Updates
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
NCT06545942
Recruiting
This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313 administered orally as a single agent or combination therapy in patients with homologous recombinant deficient solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/29/2025
Locations: Investigative Site #110, Saint Louis, Missouri
Conditions: Advanced Solid Tumor, Metastatic Solid Tumor, Prostate Cancer, Pancreas Cancer, Breast Cancer, Ovarian Cancer, Homologous Recombination Deficiency
Register for Updates
Addressing Under-treatment and Health Equity in AS and MR Using an Integrated EHR Platform
NCT06099665
Recruiting
This multi-center, prospective, cluster-randomized controlled trial will evaluate Tempus Next automated notifications as an intervention to support identification and evaluation of patients possibly indicated for Valve Intervention (VI). This study will evaluate the impact of Tempus Next's automated notifications on: (1) Transcatheter or surgical procedure for AS or MR; and (2) Clinic visit with at least one member of the Multidisciplinary Heart Team (including time to evaluation) for patients w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/29/2025
Locations: Saint Luke's Health System, Kansas City, Missouri
Conditions: Aortic Valve Stenosis, Mitral Regurgitation
Register for Updates
Ferric Citrate and Chronic Kidney Disease in Children
NCT04741646
Recruiting
We will conduct a 12-month, double-blind, randomized, placebo-controlled trial to assess the effects of therapy with ferric citrate (FC) on changes in intact FGF23 levels (iFGF23, primary endpoint) in 160 pediatric patients (80 in each of the two arms) aged 6-18 years of either sex with chronic kidney disease (CKD) stages 3-4 and age-appropriate normal serum phosphate levels. Participants will be randomized to one of the two groups: 1) FC or 2) FC placebo. Participants will be recruited from 20... Read More
Gender:
ALL
Ages:
Between 6 years and 18 years
Trial Updated:
04/29/2025
Locations: Children's Mercy Hospital, Kansas City, Kansas City, Missouri
Conditions: Chronic Kidney Diseases
Register for Updates
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
NCT06120140
Recruiting
The purpose of this study is to evaluate whether enhanced dermatologic management can reduce incidence of grade greater than or equal to (\>=) 2 dermatologic adverse events of interest (DAEIs) when compared with standard-of-care skin management in participants with locally advanced or metastatic stage IIIB/C-IV epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) treated first-line with amivantamab and lazertinib. A substudy will enroll participants from Arms A and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: Oncology Hematology Associates, Springfield, Missouri
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers
NCT05616624
Recruiting
In this study, patients with small cell or non-small cell lung cancer will receive ADI-PEG 20, gemcitabine, and docetaxel after demonstrated progression on frontline therapy. In phase I of the study, up to 6 dose levels will be tested to find the recommended phase II dose (RP2D), after which patients enrolling to phase II will be treated at that dose level to assess efficacy. Although safety and tolerability has been previously determined in the sarcoma population, dose de-escalations of the che... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Non Small Cell Lung Cancer, Non-small Cell Lung Cancer, Small-cell Lung Cancer, Small Cell Lung Carcinoma
Register for Updates
Patients At Risk for Sensory Screening (HPARSS) to Enhance Sensory Deficit Screening in Childhood Cancer Survivors
NCT05582551
Recruiting
The overall goal of this study is to attempt to overcome the organizational barriers that impede prompt screening for at-risk sensory deficits in childhood cancer survivors (CCS). Using a cross sectional design study, collaborators in the Informatics Research branch of the Institute of Informatics at the Washington University School of Medicine will identify CCS at risk for sensory deficits based upon their therapy exposure to generate the highlighting patients at risk for sensory screening (HPA... Read More
Gender:
ALL
Ages:
Between 7 years and 17 years
Trial Updated:
04/28/2025
Locations: St. Louis Children's Hospital - Washington University School of Medicine, Saint Louis, Missouri
Conditions: Childhood Cancer
Register for Updates
Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
NCT04202341
Recruiting
Long-term, multicenter, multinational, observational, registry of patients with gMG that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT) such as eculizumab (Soliris®) and ravulizumab (Ultomiris®).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: Clinical Trial Site, Columbia, Missouri
Conditions: Generalized Myasthenia Gravis
Register for Updates
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
NCT06767514
Recruiting
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Clinical Study Site, Kansas City, Missouri
Conditions: Non-Small Cell Lung Cancer
Register for Updates